Abstracts tagged "Hydroxychloroquine"

Abstract Number: 1964 • 2017 ACR/ARHP Annual Meeting
The Risk of Hydroxychloroquine Toxic Retinopathy and Its Risk Factors in the Treatment of Rheumatic Diseases: A Systematic Review
April Jorge¹, Sharan K. Rai² and Hyon K. Choi², ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) is widely used in the treatment of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and other rheumatic diseases. While generally well-tolerated and…
Abstract Number: 2035 • 2017 ACR/ARHP Annual Meeting
Clinical Audit of Hydroxychloroquine Dosing and Toxicity Screening in Patients with Inflammatory Arthritis and Connective Tissue Diseases
Sahil Koppikar¹ and Henry Averns², ¹Department of Rheumatology, University of Toronto, Toronto, ON, Canada, ²Private Practice, Kingston, ON, Canada
Background/Purpose: Hydroxychloroquine (HCQ) is used widely for the treatment of inflammatory arthritides and systemic lupus erythematosus. Recent publications have shown that HCQ toxicity is not…
Abstract Number: 2596 • 2017 ACR/ARHP Annual Meeting
Hydroxychloroquine Use Is Associated with Decreased Dendritic Cell Activation and Thrombolytic Factors in SLE Patients
Samantha Slight-Webb¹, Rufei Lu², Hua Chen¹, Holden T. Maecker³, Paul J. Utz⁴, Joel M. Guthridge⁵ and Judith A. James⁶, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Medicine, Stanford University School of Medicine, Stanford, CA, ⁵Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The antimalarial drug hydroxychloroquine (HCQ) has been used for decades to treat various rheumatic diseases including systemic lupus erythematosus (SLE). The efficacy of HCQ…
Abstract Number: 2614 • 2017 ACR/ARHP Annual Meeting
Hydroxychloroquine Initiation Dosing Trends and Predictors in Systemic Lupus Erythematosus
April Jorge¹, Leo Lu², Yuqing Zhang³, Sharan K. Rai⁴, Lucy H. Young⁵, Ronald B. Melles⁶, Michael F. Marmor⁷, Karen H. Costenbader⁸, Rosalind Ramsey-Goldman⁹, S. Sam Lim¹⁰, John M. Esdaile¹¹, Ann E. Clarke¹², Murray Urowitz¹³, Anca Askanase¹⁴, Cynthia Aranow¹⁵, Michelle Petri¹⁶ and Hyon K. Choi⁴, ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³School Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Department of Ophthalmology,, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, ⁶Department of Ophthalmology, Kaiser Permanente, Redwood City, CA, ⁷Department of Ophthalmology and Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA, ⁸Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁹FSM, Northwestern University, Chicago, IL, ¹⁰Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ¹¹Arthritis Research Canada, Richmond, BC, Canada, ¹²Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ¹³Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹⁴Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ¹⁵Autoimmune and Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhasset, NY, ¹⁶Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD
Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone of systemic lupus erythematosus (SLE) care. The major long-term adverse event risk is vision-threatening toxic retinopathy. The 2012 EULAR,…
Abstract Number: 2618 • 2017 ACR/ARHP Annual Meeting
Why Aren’t All Patients with SLE Taking Hydroxychloroquine? A Retrospective Chart Review
Caroline H. Siegel¹, Jennifer M. Grossman¹, John Fitzgerald¹, Bevra H. Hahn^1,2, Lori Sahakian¹, Eloise Olmos² and Maureen A. McMahon¹, ¹UCLA David Geffen School of Medicine, Los Angeles, CA, ²Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Although previous SLE treatment guidelines recommended judicious use of antimalarials, there is a growing body of evidence demonstrating that HCQ prevents flares, protects against…
Abstract Number: 2635 • 2017 ACR/ARHP Annual Meeting
Dosechecker: Solving the Hydroxychloroquine Dosing Dilemma with a Smart Phone App
Elliot Perlman¹, Robert Friday², Paul Greenberg³, David Browning⁴ and Joan Miller⁵, ¹Rhode Island Eye Institute, Providence, RI, ²Division of Rheumatology, Department of Medicine, Newton-Wellesley Hospital, Newton, MA, ³Division of Ophthalmology, Alpert Medical School, Brown University, Providence, RI, ⁴Charlotte Eye Ear, Nose, and Throat Associates, Charlotte, NC, ⁵Department of Ophthalmology, Harvard Medical School and Massachusetts Eye and Ear Institute, Boston, MA
Background/Purpose: Hydroxychloroquine retinopathy (HCR) is a potentially blinding but largely preventable disease. The true prevalence of HCR is unknown among the 350,000 Americans who take…
Abstract Number: 340 • 2016 ACR/ARHP Annual Meeting
Hydroxychloroquine: A Potential Treatment for Osteoporosis By Osteoclast Inhibition!
Tim Both¹, Paul L. van Daele² and Bram Van der Eerden¹, ¹Internal Medicine, Erasmus MC, Rotterdam, Netherlands, ²Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: We recently showed that patients with primary Sjögren Syndrome (pSS) have significantly higher bone mineral density (BMD) in the lumbar spine and femoral neck…
Abstract Number: 3134 • 2016 ACR/ARHP Annual Meeting
Hydroxychloroquine Is Not Effective in Reducing Symptoms of Hand Osteoarthritis: Results from a Placebo-Controlled Randomised Trial
Sarah R. Kingsbury¹, Puvan Tharmanathan², Ada Keding³, Sarah Ronaldson³, Andrew Grainger⁴, Richard J. Wakefield⁵, Catherine Arundel³, Fraser Birrell⁶, Michael Doherty⁷, Tonia Vincent⁸, Fiona E Watt⁹, Krysia Dziedzic¹⁰, Terence W. O'Neill¹¹, Nigel K Arden¹², David L Scott¹³, John Dickson¹⁴, Toby Garrood¹⁵, Michael Green^16,17, Ajit Menon¹⁸, Tom Sheeran¹⁹, David Torgerson³ and Philip G. Conaghan⁴, ¹Section of Musculoskeletal Disease, Chapel Allerton Hospital, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, Leeds, United Kingdom, ²University of York, York, United Kingdom, ³Health Sciences, University of York, York, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵University of Leeds, Leeds, United Kingdom, ⁶Institute for Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁷Academic Rheumatology, University of Nottingham, Nottingham, Great Britain, ⁸University of Oxford, London, Great Britain, ⁹Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ¹⁰Institute for Primary Care and Health Sciences, Keele University, Staffordshire, United Kingdom, ¹¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Centre for Musculoskeletal Research, Manchester, United Kingdom, ¹²Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom, ¹³Department of Rheumatology, King's College London, London, United Kingdom, ¹⁴South Tees Hospitals NHS Foundation Trust, Middlesbrough, United Kingdom, ¹⁵Rheumatology, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom, ¹⁶York Teaching Hospital NHS Foundation Trust, York, United Kingdom, ¹⁷Harrogate and District NHS Foundation Trust, Harrogate, United Kingdom, ¹⁸Haywood Hospital, Stoke-On-Trent, United Kingdom, ¹⁹Cannock Chase Hospital, Cannock, United Kingdom
Background/Purpose: Synovitis is prevalent in OA and associated with pain. Hydroxychloroquine (HCQ) is used routinely for treating synovitis in inflammatory arthritis. The primary aim of…
Abstract Number: 435 • 2016 ACR/ARHP Annual Meeting
It Takes Two, an Interdisciplinary Approach to Increasing Hydroxychloroquine Screening Adherence
Christina Downey¹, Tombra Govina¹ and Eric Newman², ¹Geisinger Medical Center, Danville, PA, ²Department of Rheumatology, Geisinger Medical Center, Danville, PA
Background/Purpose: Hydroxychloroquine (HCQ) is a widely used rheumatologic drug that carries a risk for irreversible retinal toxicity. The incidence of adverse effect increases to greater…
Abstract Number: 436 • 2016 ACR/ARHP Annual Meeting
Are Providers Recommending Appropriate Screening for Hydroxychloroquine-Induced Retinal Toxicity to Their Patients?
Sarah Haserodt¹, Chris Tonner², Gabriela Schmajuk³ and Jinoos Yazdany⁴, ¹Internal Medicine, California Pacific Medical Center, San Francisco, CA, ²Rheumatology, University of California, San Francisco, San Francisco, CA, ³San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Although well tolerated by most patients, hydroxychloroquine (HCQ) can cause irreversible retinal damage. The American Association of Ophthalmology (AAO) 2016 Guidelines recommend a baseline…
Abstract Number: 652 • 2016 ACR/ARHP Annual Meeting
The Reasons for Discontinuation of Combination Therapy with Methotrexate and Tumor Necrosis Factor Inhibitors Versus Triple Therapy Differ Significantly Because of Higher Adverse Events with Triple Therapy
Daniel Erhardt¹, Brian C Sauer², Chia-Chen Teng², Ted R. Mikuls³, Jeffrey R. Curtis⁴ and Grant W. Cannon², ¹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: We recently reported that real-world persistence in Veteran’s Affairs (VA) patients was lower in Rheumatoid arthritis (RA) patients receiving triple therapy [methotrexate (MTX), sulfasalazine…
Abstract Number: 737 • 2016 ACR/ARHP Annual Meeting
Hydroxychloroquine Whole Blood Levels Do Not Associate with Hydroxychloroquine Retinopathy
Michelle Petri¹, Wei Fu² and Syed Mahmood Shah³, ¹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The American Academy of Ophthalmology guidelines on hydroxychloroquine retinopathy were recently revised (Ophthalmology 2016;1-9). These guidelines recommend optical coherence tomography (OCT) with multifocal electroretinogram…
Abstract Number: 741 • 2016 ACR/ARHP Annual Meeting
Hydroxychloroquine Is Not Associated with Hemolytic Anemia in Glucose-6-Phosphate Dehydrogenase (G6PD) Deficient Patients
Samya Mohammad, Megan E. B. Clowse, Amanda Eudy and Lisa Criscione-Schreiber, Division of Rheumatology, Department of Medicine, Duke University, Durham, NC
Background/Purpose: Hydroxychloroquine (HCQ) is frequently used to treat autoimmune diseases. The HCQ package insert and online drug information resources report an increased risk of hemolytic…
Abstract Number: 751 • 2016 ACR/ARHP Annual Meeting
Complement C4d Split Products on Erythrocytes Are Associated with Composite Measure of Disease Activity in Systemic Lupus Erythematosus Subjects Receiving Methotrexate and Hydroxychloroquine
Michelle Petri¹, Ying Qu², John Conklin³, Kelley Brady⁴, Robert Apilado⁵ and Thierry Dervieux⁶, ¹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ²Exagen Diagnostics, Vista, CA, ³1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁴R&D, Exagen Diagnostics, Vista, CA, United Kingdom, ⁵Exagen Diagnostics, vista, CA, United Kingdom, ⁶Research and Development, Exagen Diagnostics, Vista, CA
Background/Purpose: We evaluated the relationships between disease activity measures and C4d split products on erythrocytes (EC4d) in SLE subjects from a subset of the Hopkins…
Abstract Number: 752 • 2016 ACR/ARHP Annual Meeting
Anti-Ro Positivity Is a Predictor of Responsiveness to Topical Steroids or Hydroxychloroquine in Patients with Discoid but Not Subacute Cutaneous Lupus
Rajaie Namas¹, Corey Powell² and J. Michelle Kahlenberg³, ¹Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, ²Consulting for Statistics, Computing and Analytics Research, University of Michigan, Ann Arbor, MI, ³Internal Medicine, Division of Rheumatology, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Cutaneous lupus erythematosus (CLE) lesions are difficult to treat and medications are often chosen based only on provider experience. Thus, we chose to assess…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].